Correlation found between change in IOP and conjunctival hyperaemia induced by latanoprost

Article

A strong correlation between a change in intraocular pressure (IOP) and conjunctival hyperaemia severity induced by latanoprost has been confirmed in a recent study.

A strong correlation between a change in intraocular pressure (IOP) and conjunctival hyperaemia severity induced by latanoprost has been confirmed in a recent study published in the Journal of Glaucoma.

Drs Hiroshi and Kaori Kobayashi, from Amagasaki Hospital, Hyogo and Osaka Red Cross Hospital, Osaka, Japan, respectively, examined 114 patients with open-angle glaucoma or ocular hypertension. Their aim was to determine any correlation between a short-term change in conjunctival hyperaemia severity and the IOP-reducing effect induced by latanoprost.

Of the 114 patients 56 were female and 58 were male and they had a mean age of 60.9±15 years. The primary outcome of the study was to determine the change in conjunctival hyperaemia grade at day 2 and the change in IOP at 6 months after commencing latanoprost treatment.

The mean IOP before latanoprost treatment was 22.5±3.8 mmHg and after 6 months it was 16.5±2.9 mmHg (P < 0.0001). Mean changes in conjunctival hyperaemia before and after 2 days of latanoprost treatment were 0.32±0.58 and 1.74±1.11, respectively (P < 0.0001). It was found that the mean change in IOP was greater in eyes with a higher hyperaemia grade change.

In conclusion, the researchers found a significant correlation between the change in IOP and the conjunctival hyperaemia severity after treatment with latanoprost.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.